Bessemer Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Bessemer Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-136,606	Closed	-$4.29M	–	2568
2026 Q2	$4.29M	Sell	136,606 -2,345	-2%	-$69.2K	0.01%	622
2026 Q1	$3.44M	Buy	138,951 +304	+0.2%	+$7.24K	0.01%	625
2025 Q4	$3.24M	Buy	138,647 +135,161	+3,877%	+$3.01M	0.01%	617
2025 Q3	$69K	Buy	3,486 +2,678	+331%	+$55.1K	﹤0.01%	1352
2025 Q2	$18K	Buy	808 +275	+52%	+$6.49K	﹤0.01%	1595
2025 Q1	$13K	Buy	533 +100	+23%	+$2.25K	﹤0.01%	1669
2024 Q4	$9K	Buy	433 +204	+89%	+$4.38K	﹤0.01%	1796
2024 Q3	$5K	Buy	229 +122	+114%	+$2.26K	﹤0.01%	1904
2024 Q2	$2K	Hold	107	–	–	﹤0.01%	1930
2024 Q1	$2K	Hold	107	–	–	﹤0.01%	1930
2023 Q4	$2K	Hold	107	–	–	﹤0.01%	2012
2023 Q3	$1K	Hold	107	–	–	﹤0.01%	2061
2023 Q2	$1K	Buy	+107	New	+$1.54K	﹤0.01%	2134

Other funds holding CPRX

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Bessemer Group's CPRX Position: Q3 2026 in Review

Bessemer Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 136,606 shares — an estimated $4.29M sold.

Bessemer Group first reported a position in CPRX in Q2 2023 and held it in 13 quarters. The position peaked at $4.29M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Bessemer Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Bessemer Group sold 136,606 Catalyst Pharmaceutical shares in Q3 2026, an estimated $4.29M.
Bessemer Group first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 13 quarters.
Bessemer Group's Catalyst Pharmaceutical position peaked at $4.29M in Q2 2026.
2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.